The U.S. fertility rate reached a new low in 2024, CDC data show
The U.S. was once among only a few developed countries with a rate that ensured each generation had enough children to replace itself — about 2.1 kids per woman. But it has been sliding in America for close to two decades as more women are waiting longer to have children or never taking that step at all.
The new statistic is on par with fertility rates in western European countries, according to World Bank data.
Alarmed by recent drops, the Trump administration has taken steps to increase falling birth rates, such as issuing an executive order meant to expand access to and reduce costs of in vitro fertilization and backing the idea of 'baby bonuses' that might encourage more couples to have kids.
But there's no reason to be alarmed, according to Leslie Root, a University of Colorado Boulder researcher focused on fertility and population policy.
'We're seeing this as part of an ongoing process of fertility delay. We know that the U.S. population is still growing, and we still have a natural increase — more births than deaths,' she said.
The U.S. Centers for Disease Control and Prevention released the statistic for the total fertility rate with updated birth data for 2024.
In the early 1960s, the U.S. total fertility rate was around 3.5, but plummeted to 1.7 by 1976 after the Baby Boom ended. It gradually rose to 2.1 in 2007 before falling again, aside from a 2014 uptick. The rate in 2023 was 1.621, and inched down in 2024 to 1.599, according to the CDC's National Center for Health Statistics.
Birth rates are generally declining for women in most age groups — and that doesn't seem likely to change in the near future, said Karen Guzzo, director of the Carolina Population Center at the University of North Carolina.
People are marrying later and also worried about their ability to have the money, health insurance and other resources needed to raise children in a stable environment.
'Worry is not a good moment to have kids,' and that's why birth rates in most age groups are not improving, she said.
Asked about birth-promoting measures outlined by the Trump administration, Guzzo said they don't tackle larger needs like parental leave and affordable child care.
'The things that they are doing are really symbolic and not likely to budge things for real Americans,' she said.
The CDC's new report, which is based on a more complete review of birth certificates than provisional data released earlier this year, also showed a 1% increase in births — about 33,000 more — last year compared to the prior year.
That brought the yearly national total to just over 3.6 million babies born.
But this is different: The provisional data indicated birth rate increases last year for women in their late 20s and 30s. However, the new report found birth rate declines for women in their 20s and early 30s, and no change for women in their late 30s.
What happened? CDC officials said it was due to recalculations stemming from a change in the U.S. Census population estimates used to compute the birth rate.
That's plausible, Root said. As the total population of women of childbearing age grew due to immigration, it offset small increases in births to women in those age groups, she said.
Stobbe writes for the Associated Press. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
15 minutes ago
- Boston Globe
FDA vaccine chief leaving agency after less than 3 months
Prasad joined the FDA in May after years as an academic researcher at the University of California San Francisco, where he frequently criticized the FDA's approach to drug approvals and COVID-19 vaccines. Advertisement His contrarian approach appeared to match FDA Commissioner Marty Makary, who repeatedly praised Prasad's work and intellect. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up But in recent weeks Prasad became a target of conservative activists, including Laura Loomer, who flagged Prasad's past statements criticizing Trump and praising liberal independent Senator Bernie Sanders. 'How did this Trump-hating Bernie Bro get into the Trump admin???' Loomer posted on X last week. Prasad also attracted scrutiny for his handling of a recent safety issue surrounding the only approved gene therapy for Duchenne's muscular dystrophy. Under his direction, shipments of the therapy were briefly halted after a series of patient deaths, then resumed late Monday following vocal pushback from families of boys with the fatal muscle-wasting disorder. Prasad has long been skeptical of the therapy and other muscular dystrophy drugs sold by the drugmaker, Sarepta Therapeutics. As an academic, Prasad gained prominence by attacking the FDA for being too lenient in its standards for approving cancer drugs and other new therapies. Advertisement That approach is at odds with Trump's Republican supporters, who generally favor speedier approvals and unfettered access to experimental treatments. During Trump's first term he signed the " Right to Try " law, a largely symbolic piece of legislation that won popular support from conservatives seeking to give dying patients expanded access to unproven drugs. Prasad's decision to pause Sarepta's therapy was criticized last week by a columnist and the editorial board of The Wall Street Journal. Separately, Prasad's division issued rejection letters this month to three small biotech firms seeking approval for new gene therapies. Prasad's predecessor in the role, Dr. Peter Marks, oversaw a steep rise in approvals for new gene therapies, which aim to treat or prevent disease by replacing or modifying a portion of patients' genetic code. Prasad has been an outspoken critic of Marks' leadership at FDA. which included overseeing the approval of the first COVID vaccines and therapies.
Forbes
15 minutes ago
- Forbes
Forget Screen Time, This Is The True Threat To Gen Alpha
CEOs and founders are finally beginning to pay attention to the mobility-gap in our youth. While all eyes are on mobile phones as the greatest threat to our youth's wellbeing, a bigger threat to childhood might be unfolding just beyond the glow of those screens. Across the globe, we're raising a generation that is less physically active, less mobile, and less confident in their bodies than ever before. In the United States, only 20-28% of kids between ages 6 and 17 meet the CDC's recommendation of 60 minutes of daily physical activity. Globally, the situation is even more dire, with over 80% of adolescents not getting enough exercise, according to the World Health Organization. Despite decades of awareness campaigns, public investment, and school initiatives, the needle has barely moved. The consequences ripple out beyond rising obesity or declining cardiovascular health. Lower levels of childhood movement are linked to decreased executive function, poorer mental health, reduced school performance, and higher rates of social isolation. In short, we're quietly undermining an entire generation that will soon find itself struggling not only with their physical well-being, but with the confidence and competence that comes from mastering their own bodies, all in the era of AI that is already making it more difficult for humans to compete. This is why we need to look beyond our concerns over the screen, and examine how we can push and pull our youth to action again. And in this endeavor, companies and their leadership have much more work to do than you might initially think. We Need to Pull Kids Toward Movement, Not Push Them Away From Screens If we want to raise kids who move, we need to build environments that make movement feel rewarding, natural, and most of all, fun. It is not enough to tell children to go outside or scold them for spending too much time online. The same goes for simply taking away their cellphones, even if Jonathan Haidt has made a wonderful case for doing so. Instead, we need to offer meaningful incentives that meet them, and move them, where they are. That's the idea behind WeWard, a free mobile app that turns walking into a rewarding experience. 'When we gamify movement, teenagers suddenly care,' says Yves Benchimol, WeWard's founder and CEO in an interview. 'Across our user base, daily movement jumps by 24 percent once rewards kick in.' Clearly the carrot approach is working, given how one of WeWard's fastest-growing user segments has been among teens and young adults who never saw themselves as 'active.' According to Benchimol, 'The magic doesn't come from collecting points or the gamification alone. The social proof of it all is incredibly important as well. When you're competing with your friends and building healthier habits through community, that's a powerful shift in mindset.' He's particularly passionate about closing mobility equity gaps with methods that pull, instead of push, and he also reminds us of the importance of access to options to move. 'There's a turbo fitness culture these days that promotes rigid diets and expensive workout routines that not everyone can afford,' Benchimol says. 'A healthy lifestyle is something that everyone should have access to in a way that isn't intimidating or extreme. That's why we chose to focus on walking—it's a simple but powerful movement that's incredibly overlooked. Educating the youth on these benefits will be key to wellness reform' What Benchimol is highlighting ties to a growing trend where treating physical activity not as a personal virtue, but as a public good that needs private solutions and education to play a larger role. If we want more movement, we need to design for it on all sides of the economy. That includes smart incentives, but also the resources and tools to make movement easy. Make Mobility Accessible, And The Rest Takes Care of Itself Kids find the joy in mobility early, if only we allow it. For many kids, a love of motion starts the moment they ride their first bike. But fewer and fewer are reaching that milestone, in large part given that we simply don't have access to spaces, or equipment to move the way previous generations did. Perhaps the most striking statistic comes from something as simple as riding a bike. According to Strider Bikes founder Ryan McFarland during our interview, 'Only about a quarter of kids in the U.S. can ride a bike by the time they're six. We used to take it for granted. Now, it's the exception.' Seeing these statistics play out firsthand is part of the reason McFarland created the Strider balance bike to begin with. After watching his own son struggle on traditional learn-to-ride toys that were too cumbersome and complicated, he crafted his own pedal-less starter bike designed to teach balance and confidence before introducing propulsion. 'Balance first, propulsion later. The moment a toddler glides, you've banked a lifetime of confidence,' McFarland says. Recognizing the challenge accessibility poses, McFarland has pushed the company to do more than simply build bikes. The Strider Education Foundation helped launch and now supports All Kids Bike, a nonprofit initiative that puts balance bikes directly into public school kindergarten PE classes. Their turnkey program includes bikes, helmets, curriculum, and teacher training, all funded by donors. 'With over 1,600 active programs in all 50 states, we're reaching 160,000 five-year-olds every year,' says Lisa Weyer, executive director of All Kids Bike. 'And because the equipment lasts up to a decade, we are teaching over 1.6 million kids how to ride.' The appeal to schools is clear: the program fits seamlessly into existing curriculum, doesn't require families to buy their own equipment, and provides measurable outcomes. 'We treat bikes the way we treat books or microscopes,' Weyer explains. 'Bikes shouldn't feel like luxury items. They're essential learning tools and the pathway to a lifetime of mobility.' Both Weyer and McFarland see mobility as a justice issue. 'You don't get to build confidence if you never get the chance to try,' says McFarland. 'That's why we focus on public schools, especially in communities where bikes might be out of reach.' When we break down the barriers of accessibility by removing cost barriers, creating access, and integrating movement into daily routines, kids naturally take to it in ways that show the issue is not due to a lack of interest in movement. Quite the contrary. However, there's another piece of the puzzle: adults modeling the behavior they wan't to see in the youth. Don't Forget Grown-ups Need Play, Too Those who have been around kids know that they model what we do, not what we say. If kids are watching us, and they always are, then they need to see adults enjoying movement, not avoiding it. Given the only race most kids see their parents run is of the rat variety, we have ourselves to blame for much of the lack of movement we see in our progeny. Bringing back movement that is fun to our own lives is an essential starting point that we can't shut our eyes from. And that's where companies like Onewheel come in. 'The idea for Onewheel was inspired by the desire to recreate the feeling of freedom and flow that I first fell in love with growing up snowboarding in the Canadian Rockies,' says Kyle Doerksen, founder of Onewheel, a self-balancing electric board that feels like surfing on land. 'It was never meant to be a toy, but a vehicle that could create a whole new category of sport, and turn the everyday school or coffee run into a micro-adventure.' What began as a Kickstarter project in 2014 has grown into a global community with riders in 139 countries around the world and an active scene of meetups, group rides, and competitions. 'People love to ride together, and we see a lot of parents and older kids who ride together too,' Doerksen adds. 'There's this deep nostalgia for the kind of play we had as kids, exploration, speed, freedom, that I think sometimes we as adults forgot was possible.' The company's latest board is itself a nostalgic nod to the past, the Onewheel XR Classic, a reimagined version of its best-selling board, the discontinued Onewheel XR. Doerksen argues that micromobility is at its core a cultural shift. 'When parents ride to the park instead of driving, when they try and fail and laugh and try again, kids notice. Adults need recess, too.' By making movement aspirational for grown-ups, Onewheel has created a feedback loop: adults who play raise kids who move. And when that loop becomes normal, the next generation doesn't need to be coaxed off the couch. We can't lecture our way out of the youth mobility crisis. What we can do is make moving irresistible. That means more carrots, rewards, recognition, community, and fewer sticks. It means embedding equipment and encouragement where kids already are: schools, parks, city blocks. It means showing them that movement is normal, joyful, and for everyone. Above all, it means treating mobility not as a side effect of good parenting or elite schooling, but as a basic ingredient in a thriving childhood. The bodies of the next generation are already telling us what they need. Our job is to listen, and get them moving.
16 minutes ago
FDA vaccine chief leaving agency after less than 3 months
WASHINGTON -- The Food and Drug Administration's polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of biotech companies, patient groups and conservative allies of President Donald Trump. Dr. Vinay Prasad 'did not want to be a distraction' and was stepping down from his role as the FDA's top vaccine regulator 'to spend more time with his family,' a spokesperson for the Department of Health and Human Services said in a statement late Tuesday. Two people familiar with the situation told The Associated Press that Prasad was ousted following several recent controversies. The people spoke on condition of anonymity to discuss internal personnel matters. Prasad joined the FDA in May after years as an academic researcher at the University of California San Francisco, where he frequently criticized the FDA's approach to drug approvals and COVID-19 vaccines. His contrarian approach appeared to match FDA Commissioner Marty Makary, who repeatedly praised Prasad's work and intellect. But in recent weeks Prasad became a target of conservative activists, including Laura Loomer, who flagged Prasad's past statements criticizing Trump and praising liberal independent Senator Bernie Sanders. 'How did this Trump-hating Bernie Bro get into the Trump admin???' Loomer posted on X last week. Prasad also attracted scrutiny for his handling of a recent safety issue surrounding the only approved gene therapy for Duchenne's muscular dystrophy. Under his direction, shipments of the therapy were briefly halted after a series of patient deaths, then resumed late Monday following vocal pushback from families of boys with the fatal muscle-wasting disorder. Prasad has long been skeptical of the therapy and other muscular dystrophy drugs sold by the drugmaker, Sarepta Therapeutics. As an academic, Prasad gained prominence by attacking the FDA for being too lenient in its standards for approving cancer drugs and other new therapies. That approach is at odds with Trump's Republican supporters, who generally favor speedier approvals and unfettered access to experimental treatments. During Trump's first term he signed the ' Right to Try ' law, a largely symbolic piece of legislation that won popular support from conservatives seeking to give dying patients expanded access to unproven drugs. Prasad's decision to pause Sarepta's therapy was criticized last week by a columnist and the editorial board of The Wall Street Journal. Separately, Prasad's division issued rejection letters this month to three small biotech firms seeking approval for new gene therapies. Prasad's predecessor in the role, Dr. Peter Marks, oversaw a steep rise in approvals for new gene therapies, which aim to treat or prevent disease by replacing or modifying a portion of patients' genetic code. Prasad has been an outspoken critic of Marks' leadership at FDA. which included overseeing the approval of the first COVID vaccines and therapies.
